PRVB Provention Bio, Inc.

8.75-0.29 (-3.21%)
Close: November 21, 2019

Quote

Previous Close
$8.75
Day Range
$8.71-$9.25
52 Week Range
$1.52-$22.82
Volume
407,195
Avg Volume
399,203
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$416.83M
Enterprise Value (EV)
$372.11M
PE Ratio
-
EV/EBITDA
NAN
Price/Sales
-
Price/Book
6.99
PEG Ratio
0.43

Financials

Revenue
-
Gross Profit
-
EBITDA
-
EPS, ttm
-$1.01
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
3/24/2020 (123 days)
Debt to Equity
-
Debt
$13.82M
Cash
$58.54M
Net Debt
-

Performance

Beta
1.01
200 Day Moving Avg
$6.67
50 Day Moving Avg
$7.46
52 Week Change
236.06%
YTD Change
355.68%
1 Month Change
48.93%
3 Month Change
-13.49%
6 Month Change
137.89%
1 Year Change
236.06%
2 Year Change
87.94%
5 Year Change
87.94%

Share Count

Shares Outstanding
47.6M
Float
32.0M
Restricted Shares
15.6M
Restricted Shares, %
32.72%

Provention Bio, Inc. Company Details

Sector: Health Technology

Industry: Pharmaceuticals: Major

CEO: Ashleigh W. Palmer

Website: http://www.proventionbio.com

Description: Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn's disease; PRV-300 for ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of T1D onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.

Employees: 13